This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bellamy, W. T. Articles by Grogan, T. M. Search for Related Content PubMed PubMed Citation Articles by Bellamy, W. T. Articles by Grogan, T. M.

American Journal of Pathology, Vol 142, 691-698, Copyright © 1993 by American Society for Investigative Pathology

REGULAR ARTICLES

An in vivo model of human multidrug-resistant multiple myeloma in SCID mice

WT Bellamy, A Odeleye, P Finley, B Huizenga, WS Dalton, RS Weinstein, EM Hersh and TM Grogan
Department of Pathology, University of Arizona College of Medicine, Tucson.

We have established a reproducible in vivo model of human multiple myeloma in the severe combined immunodeficient (SCID) mouse using both the RPMI 8226 human myeloma cell line and the P-glycoprotein-expressing multidrug-resistant 8226/C1N subline. SCID mice 5 to 8 weeks of age were injected intraperitoneally with either 8226 drug-sensitive or P- glycoprotein-expressing multidrug-resistant myeloma cells (8226/C1N). Tumors were detected within 5 days after injection by the presence of human lambda light chain excretion in the mouse urine. Growth of the tumor was observed primarily in the abdominal cavity with spread to the abdominal organs. The anti-neoplastic agent doxorubicin was effective in treating the drug-sensitive 8226 human-SCID xenografts but had no effect on the multi-drug-resistant 8226/C1N human-SCID xenografts. In the 8226-sensitive xenografts, treatment with doxorubicin resulted in a sharp decline in the concentration of human lambda light chain being excreted in the mouse urine. This correlated with an increased survival of the drug-treated animals. This mouse model offers an in vivo means of evaluating efficacy and toxicity of new therapeutic approaches, including development of chemosensitizers directed against P- glycoprotein in multidrug-resistant myelomas.

This article has been cited by other articles:

				H. Rozemuller, E. van der Spek, L. H. Bogers-Boer, M. C. Zwart, V. Verweij, M. Emmelot, R. W. Groen, R. Spaapen, A. C. Bloem, H. M. Lokhorst, et al. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect Haematologica, July 1, 2008; 93(7): 1049 - 1057. [Abstract] [Full Text] [PDF]

				L. M. Pilarski, G. Hipperson, K. Seeberger, E. Pruski, R. W. Coupland, and A. R. Belch Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice Blood, February 1, 2000; 95(3): 1056 - 1065. [Abstract] [Full Text] [PDF]

				S. Yaccoby, B. Barlogie, and J. Epstein Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations Blood, October 15, 1998; 92(8): 2908 - 2913. [Abstract] [Full Text] [PDF]

				M. Urashima, B. P. Chen, S. Chen, G. S. Pinkus, R. T. Bronson, D. A. Dedera, Y. Hoshi, G. Teoh, A. Ogata, S. P. Treon, et al. The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone Marrow Blood, July 15, 1997; 90(2): 754 - 765. [Abstract] [Full Text] [PDF]